BrainStorm Cell Therapeutics (NASDAQ:BCLI) announces that it has established a new clinical development program aimed at using NurOwn to treat Alzheimer’s disease (AD).
It is planning a Phase 2 clinical trial evaluating the autologous cell therapy in patients with prodromal (appearance of initial symptoms)-to-mild AD.
The company is also developing NurOwn for amyotrophic lateral sclerosis (ALS) and progressive multiple sclerosis (MS).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.